A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2024
The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.
Epistemonikos ID: 5a1e86491a50177b760fe07b32f25e63bcca55f4
First added on: Apr 17, 2025